Exploring blood markers related to diabetic peripheral neuropathy
The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy
This study looks at how certain blood markers might be connected to diabetic peripheral neuropathy in over 1000 people to better understand the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1400 (estimated) |
| Sex | All |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University Academic / other |
| Locations | 1 site (Wenzhou, Zhejiang) |
| Trial ID | NCT06041412 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between specific blood indicators and diabetic peripheral neuropathy (DPN) across multiple centers, involving over 1000 participants. Clinical data, including demographic information, blood biochemical markers, and electromyography results, will be collected from patients' electronic health records. All participants will provide informed consent, and the study protocol has received ethical approval from the First Affiliated Hospital of Wenzhou Medical University.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have undergone nerve conduction examinations via electromyography.
Not a fit: Patients with conditions such as chronic liver disease, kidney disease, or severe respiratory diseases, among others, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how blood markers influence diabetic peripheral neuropathy, potentially leading to improved diagnostic and treatment strategies.
How similar studies have performed: While the relationship between blood markers and diabetic peripheral neuropathy has been explored in other studies, this specific approach is novel and may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients who had undergone nerve conduction examination by electromyography. Exclusion Criteria: * pregnancy and lactation; chronic liver disease, kidney disease, arrhythmias, malignant diseases, severe respiratory diseases, heart failure, and acute infections; * patients with alcohol abuse; history of Autoimmune liver disease, liver disease or abnormal liver function at baseline; * parathyroid diseases (including hyperthyroidism and hypothyroidism); * pancreatitis, pancreatectomy or any transplant; * patients with malignancy and any serious concomitant disease limit the existence of life expectancy
Where this trial is running
Wenzhou, Zhejiang
- First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Binbin Deng
- Phone: dbinbin@aliyun.com
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.